Vasculitis - Diagnosis and treatment

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 5, 1999, Pages 662-677

  Gatenby, P A ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPICILLIN; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIDANOSINE; DIPYRIDAMOLE; DIURETIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; METHOTREXATE; PENICILLIN G; PREDNISOLONE; PREDNISONE; PROPYLTHIOURACIL; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; STREPTOKINASE; SULFONAMIDE; UNINDEXED DRUG; ZIDOVUDINE;

AORTA ARCH SYNDROME; GIANT CELL ARTERITIS; HUMAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; NECROTIZING ARTERITIS; POLYARTERITIS NODOSA; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0032707657     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb01614.x     Document Type: Review

References (86)

1. 1. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis - clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med 1978; 89: 660-76.
2. 2. Weedon D. The vasculopathic reaction pattern. In: Weedon D (Ed). Skin pathology. Edinburgh: Churchill Livingstone, 1997; 185-231.
3. 3. Fries J, Hunder G, Block D, Michel B et al. The American College of Rheumatology 1990 Criteria for the classification of Vasculitis. Arthritis Rheum 1990; 33: 1135-6.
4. 4. Jennette C, Falk R, Andrassy K et al. Nomenclature of systemic vasculitides. Arthritis Rheum 1994; 37: 187-92.
5. 5. Watts RA, Scott DGI. Classification and epidemiology of the vasculitides. Balliere's Clin Rheumatol 1997; 11: 191-217.
6. 6. Calabrese L, Dune G, Lie J. Vasculitis in the central nervous system. Arthritis Rheum 1997; 40: 1189-201.
7. 7. Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss Syndrome. Ann Med Interne 1992; 143: 405-16.
8. 8. Misiani R, Belluvita P, Feuili D et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinaemia. Ann Intern Med 1992; 117: 573-7.
9. 9. Mariudi J, Wakisaka A, Aizawa M et al. HLA-linked susceptibility gene of Takayasu disease. Hum Immunol 1982; 4: 87-91.
10. 10. Kerr G, Hallahan C, Giordano J et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919-29.
11. 11. Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, Mispireta J, Howritz S, Vela J. Takayasu's arteritis. Clinical study of 107 cases. Am Heart J 1997; 93: 94-103.
12. 12. Bengtsson BA, Malnivall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica: incidences of different clinical presentations and eye complications. Arthritis Rheum 1981; 24: 899-904.
13. 13. Jonasson F, Cullen JF, Elton RA. Temporal arteritis: a 14 year epidemiological clinical and prognostic study. Scot Med J 1979; 24: 111-17.
14. 14. Weyand C, Hunder N, Hicok K, Hunder G, Goronzy J. HLA-DRB1 alleles in polyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Arthritis Rheum 1994; 37: 514-20.
15. 15. Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ, Weyand CM. Giant cell vasculitis is a T cell dependent disease. Mol Med 1997; 3: 530-43.
16. 16. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121: 484-91.
17. 17. Lau H, Reid B, Weedon D. Actinic granuloma in association with giant cell arteritis: are both caused by sunlight? Pathology 1997; 29: 260-2.
18. 18. Bahlas S, Ramos-Remus C, Davis P. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1998; 25: 99-104.
19. 19. Mertens JC, Willemsen G, Van Saasa JL et al. Polymyalgia rheumatica and temporal arteritis: a retrospective study of 111 patients. Clin Rheumatol 1995; 14: 650-5.
20. 20. Hayreh S, Podhajsky P, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthal 1998; 125: 521-6.
21. 21. Editorial. Temporal artery biopsy. Lancet 1983; i: 396-7.
22. 22. Buchbinder R, Detsky A. Management of suspected giant cell arteritis - a decision analysis. J Rheumatol 1992; 19: 1220-8.
23. 23. Achkar A, Lie J, Hunder G, O'Fallon M, Gabriel S. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120: 987-92.
24. 24. Kraft H, Moller D, Volker L, Schmidt W. Color doppler ultrasound of the temporal arteries - a new method for diagnosing temporal arteritis. Klin Monatsblatter Augenheilkunde 1996; 208: 93-5.
25. 25. Chakravarty K, Elgabani S, Scott D, Merry P. Clinical audit - A district audit on the management of polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994; 33: 152-6.
26. 26. Saay KG, Enkey R, Schnitzer TJ et al. Alendronate for the treatment and prevention of glucocorticoid induced osteoporosis. N Engl J Med 1998; 339: 292-9.
27. 27. de Silva M, Hazleman BG. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double blind study. Ann Rheum Dis 1983; 45: 136-8.
28. 28. Wilke W, Hoffman G. Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am 1995; 21: 59-71.
29. 29. Leung D, Schlievert P, Meissner C. The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum 1998; 41: 1538-47.
30. 30. Royle J, Williams K, Elliott E et al. Kawasaki disease in Australia, 1993-95. Arch Dis Child 1998; 78: 33-9.
31. 31. Durongpisitkul K, Gururaj VJ, Part JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057-61.
32. 32. Dhillon R, Clarkson P, Donald AE, Powe AJ, Nash M, Novelli V et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94: 2103-6.
33. 33. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128: 146-9.
34. 34. Dawson J, Ball J, Platt R. The kidney in periarteritis nodosa. QJM Med 1948; 17: 175-202.
35. 35. Kallenberg CGM et al. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Internat 1994; 46: 1-5.
36. 36. Guillevin G, Lhote F, Amouroux J et al. Antineutrophil cytoplasmic antibodies, abdominal angiograms and pathological findings in polyarteritis nodosa and Chung-Strauss syndrome; indications for the clarification of vasculitides of the polyarteritis nodosa group. Br J Rheumatol 1992; 35: 958-64.
37. 37. Duffy J, Lidsky M, Sharp J et al. Polyarthritis, polyarteritis and hepatitis B. Medicine 1976; 55: 19-37.
38. 38. Jayne DRW, Rasmussen N, for ECSYSVASTRIAL Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European community systemic vasculitis trials study group. Mayo Clin Proc 1997; 72: 737-47.
39. 39. Savige J, Gillis D, Benson E, Davies D, Esnault V et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111: 507-13.
40. 40. Van Der Woude F, Daha M, Van Es L. The current status of neutrophil cytoplasmic antibodies. Clin Exp Immunol 1989; 78: 143-8.
41. 41. Nolle B, Specks U, Ludemann J, Rohrbach M, DeRemee R, Gross W. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener Granulomatosis. Ann Intern Med 1989; 111: 28-40.
42. 42. Rao J, Weinberger M, Oddone E, Allen N, Landsman P, Feussner J. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis: a literature review and meta-analysis. Ann Intern Med 1995; 123: 925-32.
43. 43. Carrington LB, Liebow AA. Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1996; 41: 497-527.
44. 44. De Remee RA, McDonald TJ, Harrison EG, Coles DT. Wegener's granulomatosis: anatomic correlates - a proposed classification. Mayo Clin Proc 1976; 51: 777-81.
45. 45. Andrews M, Edmunds M, Campbell A et al. Systemic vasculitis in the 1980s - is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis? J Roy Coll Phys 1990; 24: 284-8.
46. 46. Hoffman G, Kerr G, Leavitt R, Hallahan C et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
47. 47. Gross WL. Systemic necrotizing vasculitis. Balliere's Clin Rheumatol 1997; 11: 259-84.
48. 48. Exley A, Carruthers D, Luqmani R et al. Damage occurs early in systemic vasculitis and is an index of outcome. Q JM 1997; 90: 391-9.
49. 49. Savage COS, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997; 349: 553-7.
50. 50. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B et al. A prospective multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
51. 51. Adu D, Pall R, Luqmani RA et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J M 1997; 90: 401-9.
52. 52. Hoffman G. Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritis Rheum 1997; 40: 2099-104.
53. 53. De Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross W. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492-5.
54. 54. Sneller M, Hoffman G, Talar-Williams C, Kerr G, Hallahan C, Fauci A. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
55. 55. Reinhold-Keller E, de Groot K, Rudent H, Nolle B, Heller M, Gross WL. Response to trimethoprim/ sulfamethoxazole in Wegener's granulomatosis depends upon phase of disease. Q J M 1996; 89: 15-23.
56. 56. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM. Prevention of relapses in Wegener's granulomatosis by treatment with trimethoprim/ sulfamethoxazole: a multicentre placebo controlled trial in 81 patients. Clin Exp Immunol 1995; 101: 44.
57. 57. De Groot K, Reinhold-Keller E, Tatsis E et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Arthritis Rheum 1996; 39: 2052-61.
58. 58. Lockwood C. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996; 104: 77-82.
59. 59. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotising glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-63.
60. 60. Lockwood CM. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J Roy Coll Phys 1998; 32: 473-8.
61. 61. Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998; 13: 2074-6.
62. 62. Cohen Tervaert JV, Huitema MG, Hene RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-11.
63. 63. Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. Balliere's Clin Rheumatol 1997; 11: 423-46.
64. 64. Savage C, Winearls C, Evans D, Rees A, Lockwood C. Microscopic polyarteritis: presentation, pathology and prognosis. QJM 1985; 220: 467-83.
65. 65. Guillevin L, Lhote F, Cohen P et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. Arthritis Rheum 1995; 38: 1638-45.
66. 66. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341: 1620-22.
67. 67. Hubner C, Dietz A, Stremmel W, Stiehl A, Andrassy K. Macrolide-induced Churg-Strauss syndrome in a patient with atopy. Lancet 1997; 350: 563.
68. 68. Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in-patients receiving Zafirlukast. JAMA 1998; 279: 455-7.
69. 69. Green RL, Vayonis AG. Churg-Strauss syndrome after Zafirlukast in two patients not receiving systemic steroid treatment. Lancet 1999; 353: 725-6.
70. 70. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome - clinical study and long-term follow-up of 96 patients. Medicine 1999; 78: 26-37.
71. 71. Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. Medicine 1996; 75: 17-28.
72. 72. Guillevin L, Fain O, Lhote F et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. Arthritis Rheum 1992; 35: 208-15.
73. 73. Mat C, Yurdakul S, Tuzuner M, Tuzun Y. Small vessel vasculitis and vasculitis confined to skin. Balliere's Clin Rheumatol 1997; 11: 237-57.
74. 74. Szer I. Henoch-Schonlein purpura: when and how to treat. J Rheumatol 1996; 23: 1661-5.
75. 75. Watts R, Jolliffe V, Grattan C, Elliott J, Lockwood M, Scott D. Cutaneous vasculitis in a defined population -clinical and epidemiological associations. J Rheumatol 1998; 25: 920-4.
76. 76. Cupps T, Springer R, Fauci A. Chronic, recurrent small-vessel cutaneous vasculitis. Clinical experience in 13 patients. JAMA 1982; 247: 1994-2010.
77. 77. Sais G, Vidaller A, Jucgla A, Gallardo F, Peyri J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Derm 1995; 131: 1399-402.
78. 78. Mehregan KD, Hall MJ, Gibson LE. Urticarial vasculitis. A histopathologic and clinical review of 72 cases. J Am Acad Derm 1992; 26: 441-8.
79. 79. Wisnieski JJ, Baer AN, Christensen J, Cupps TR, Flagg DN et al. Hypocomplementemic urticarial vasculitis syndrome. Clinical and serological findings in 18 patients. Medicine 1995; 74: 24-41.
80. 80. Daoud MS, Hutton KP, Gibson LE. Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol 1997; 136: 706-13.
81. 81. Klein K, Pittelkow M. Tissue plasminogen activator for the treatment of livedoid vasculitis. Mayo Clin Proc 1992; 67: 923-33.
82. 82. Yiannis JA, el Azhary RA, Gibson LE. Erythema elevatum diutinum: a clinical and histopathologic study of 13 patients. J Am Acad Dem 1992; 26: 38-44.
83. 83. Mollica F, Li Volti S, Garozzo R, Russo G. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. Eur J Pediatr 1982; 151: 140-4.
84. 84. Buchanec J, Balanda V, Belakova S, Minarik M, Zibolen M. Incidence of renal complications in Schonlein-Henoch purpura syndrome in dependence of early administration of steroids. Int J Nephrol 1988; 20: 409-12.
85. 85. Oner A, Tinaztepe K, Erdogan O. The effect of triple therapy on rapidly progressive type of Henoch-Schonlein nephritis. Pediatr Nephrol 1995; 9: 6-10.
86. 86. Agnello V, Chung RT, Kaplan LM. A role of hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-5.